Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Scion Life Sciences is a New York City-based venture capital firm founded to create and build biotechnology companies focused on developing clinically transformational or curative medicines. Established by a team of experienced innovators, company-builders, and investors, Scion aims to improve human health through significant clinical impact. The firm operates from its office located at 220 East 42nd Street, New York, NY.
Over the past decade, Scion has successfully founded or built ten biotechnology companies, advancing over 15 clinical-stage therapeutics. The firm has generated more than $14 billion in public equity value and announced significant M&A proceeds, showcasing its strong momentum in the life sciences sector. Scion Life Sciences continues to attract a diverse base of limited partners who share its vision for impactful healthcare solutions.
Scion Life Sciences invests primarily in biotechnology companies that address clinically important problems. Their investment strategy emphasizes the creation of important new medicines rather than focusing solely on exits. The firm employs a disciplined approach to capital deployment, guided by three key investment pillars: mature modality, well-understood biology and pathophysiology, and standalone viability.
Scion actively seeks innovation from both academic and industry partners, as well as developing ideas internally. This approach allows them to identify and support groundbreaking therapeutics that can significantly impact patient care. The firm is particularly interested in companies that demonstrate a clear path to clinical development and have the potential to address unmet medical needs.
Scion Life Sciences has been instrumental in founding or building ten biotechnology companies over the past decade. These companies have collectively advanced over 15 clinical-stage therapeutics, contributing to a significant public equity value exceeding $14 billion. The firm’s portfolio includes companies that are focused on developing innovative treatments across various therapeutic areas.
While specific company names are not disclosed, the portfolio reflects Scion's commitment to addressing clinically important problems through the development of transformative medicines. The firm’s involvement in these companies has led to substantial M&A proceeds, further underscoring its effectiveness in the biotechnology investment space.
Samuel Hall, PhD - Managing Partner. Samuel has extensive experience in the life sciences sector, focusing on biotechnology investments and company-building initiatives.
Aaron Kantoff - Managing Partner. Aaron brings a wealth of knowledge in venture capital and operational management within the biotech industry.
Tadd Wessel - Managing Partner. Tadd has a strong background in life sciences and has been instrumental in the growth of several biotech companies.
William Chour, MD, PhD - Associate. William combines clinical expertise with investment acumen, contributing to Scion's strategic decision-making.
Lalo Flores, PhD - Venture Partner. Lalo has a deep understanding of biotechnology and has played a key role in identifying promising investment opportunities.
Samuel Hendel, PhD - Associate. Samuel focuses on evaluating scientific innovations and their potential for clinical application.
Justin Lish - Senior Associate. Justin supports the investment team in due diligence and portfolio management.
Andreas Loew, PhD - Partner. Andreas has a strong track record in biotech investments and company formation.
Huw Nash, PhD - Venture Partner. Huw brings extensive experience in drug development and commercialization.
Romesh Subramanian, PhD - Venture Partner. Romesh has a background in both academia and industry, enhancing Scion's investment strategy.
Elliot Warner, PhD - Associate. Elliot focuses on scientific evaluation and market analysis for potential investments.
Founders should pitch Scion Life Sciences via email at info@scionlifesciences.com. It is important to include a comprehensive overview of the company, the clinical problem being addressed, and the proposed solution. A well-structured pitch deck that highlights the scientific basis and market potential will enhance the chances of a positive response.
In recent months, Scion Life Sciences has continued to expand its portfolio, actively founding and building ten biotechnology companies. These companies have collectively advanced over 15 clinical-stage therapeutics, contributing to a public equity value exceeding $14 billion.
The firm has also announced significant M&A proceeds, indicating strong momentum in its investment activities. Scion's disciplined approach to capital deployment and focus on clinically important problems have positioned it as a key player in the biotechnology investment landscape.
What are Scion Life Sciences' investment criteria?
Scion Life Sciences focuses on biotechnology companies that tackle clinically important problems. They prioritize investments in companies that are developing clinically transformational or curative medicines.
How can I pitch to Scion Life Sciences?
Founders can reach out via email at info@scionlifesciences.com. It is advisable to include a detailed overview of the company, the problem being addressed, and the proposed solution in the pitch.
What makes Scion Life Sciences different from other VCs?
Scion emphasizes creating new medicines rather than focusing solely on exits. Their disciplined capital deployment strategy is guided by three investment pillars, which helps them identify high-potential opportunities in the biotech sector.
What is the geographic focus of Scion Life Sciences?
The firm primarily invests in North America, targeting biotechnology companies that are positioned to make a significant clinical impact.
What type of support does Scion Life Sciences provide to portfolio companies?
Scion Life Sciences offers operational support, strategic guidance, and access to a network of industry experts to help portfolio companies navigate the complexities of the biotechnology landscape.
What is the typical check size for investments made by Scion Life Sciences?
While specific check sizes are not disclosed, Scion employs a disciplined approach to capital deployment, indicating that they invest significant amounts in companies that align with their investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.